Caricamento...

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

BACKGROUND: Targeted therapies significantly improve clinical outcomes among patients with metastatic renal cell carcinoma (mRCC). Several new agents have been approved for first- and second-line use. However, there is a lack of compelling evidence comparing sequencing strategies, and available comp...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Pathol Oncol Res
Autori principali: Géczi, Lajos, Bodoky, György, Rokszin, György, Fábián, Ibolya, Torday, László
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Netherlands 2020
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7471136/
https://ncbi.nlm.nih.gov/pubmed/32291570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12253-020-00809-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !